Drug shortage
Ketamine Hydrochloride Injection · Hospira, Inc., a Pfizer Company
FDA drug shortage · Resolved · updated Apr 2, 2025
Key facts
| Generic name | Ketamine Hydrochloride Injection |
|---|---|
| Proprietary name | Ketamine Hydrochloride |
| Company | Hospira, Inc., a Pfizer Company |
| Presentation | Ketamine Hydrochloride, Injection, 500 mg/5 mL (100 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 0409-2051-05) |
| Dosage form | Injection |
| Strength | 500 mg/5 mL (100 mg/mL) Multiple Dose Glass Fliptop Vial |
| Status | Resolved |
| Therapeutic category | Anesthesia |
| Package NDCs | 0409-2051-05 |
| First posted | Feb 20, 2018 |
| Last updated | Apr 2, 2025 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: